Stevanato Group (NYSE:STVN) Stock Price Up 0.4% – Time to Buy?

Shares of Stevanato Group S.p.A. (NYSE:STVN) rose 0.4% during mid-day trading on Tuesday . The company traded as high as €23.60 ($24.58) and last traded at €23.43 ($24.41). Approximately 124,784 shares were traded during mid-day trading, a decline of 75% from the average daily volume of 499,775 shares. The stock had previously closed at €23.33 ($24.30).

Analyst Ratings Changes

STVN has been the topic of a number of analyst reports. Wolfe Research began coverage on Stevanato Group in a research report on Friday, December 13th. They set an “outperform” rating and a $28.00 price objective on the stock. Bank of America increased their price target on Stevanato Group from $24.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, December 13th. Finally, Morgan Stanley reissued an “equal weight” rating and issued a $23.00 price target (down previously from $24.00) on shares of Stevanato Group in a report on Tuesday, December 3rd. One equities research analyst has rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of €28.60 ($29.79).

Stevanato Group Price Performance

The company’s 50-day simple moving average is €19.95 and its 200 day simple moving average is €19.75. The company has a debt-to-equity ratio of 0.22, a quick ratio of 1.21 and a current ratio of 1.81. The company has a market cap of $6.31 billion, a PE ratio of 45.40, a PEG ratio of 10.49 and a beta of 0.59.

Stevanato Group (NYSE:STVN) last released its quarterly earnings data on Tuesday, November 5th. The company reported €0.12 ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of €0.13 ($0.14) by (€0.01) (($0.01)). The company had revenue of €277.90 million during the quarter, compared to analyst estimates of €274.36 million. Stevanato Group had a net margin of 10.47% and a return on equity of 9.86%. The business’s revenue was up 2.4% on a year-over-year basis. During the same quarter in the prior year, the company earned $0.16 EPS. On average, sell-side analysts predict that Stevanato Group S.p.A. will post 0.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Stevanato Group

Institutional investors and hedge funds have recently bought and sold shares of the stock. Schwartz Investment Counsel Inc. raised its holdings in Stevanato Group by 12.3% in the second quarter. Schwartz Investment Counsel Inc. now owns 126,281 shares of the company’s stock valued at $2,316,000 after buying an additional 13,800 shares during the period. Raymond James Trust N.A. lifted its stake in shares of Stevanato Group by 18.7% during the second quarter. Raymond James Trust N.A. now owns 10,239 shares of the company’s stock worth $188,000 after purchasing an additional 1,613 shares in the last quarter. Liontrust Investment Partners LLP purchased a new stake in shares of Stevanato Group in the second quarter worth about $6,104,000. Conestoga Capital Advisors LLC grew its stake in shares of Stevanato Group by 7.3% in the second quarter. Conestoga Capital Advisors LLC now owns 7,275,823 shares of the company’s stock valued at $133,439,000 after buying an additional 496,930 shares in the last quarter. Finally, Natixis Advisors LLC raised its holdings in shares of Stevanato Group by 27.3% during the 2nd quarter. Natixis Advisors LLC now owns 42,674 shares of the company’s stock valued at $783,000 after buying an additional 9,146 shares during the period.

Stevanato Group Company Profile

Stevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering.